# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sugar Ray Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX003-SYN
- Date: 2026-09-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Langston Pryce-Okonjo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Eleven-week review: donepezil, diabetes, hearing aids and day program. **S**

## History of present illness

Sugar Ray Robinson returns eleven weeks after intake with his care partner, two weeks after his preventive visit. He has taken donepezil 5 mg at bedtime for five weeks without nausea, diarrhea or dizziness. Off glipizide, his home glucose readings run 120 to 170 mg/dL with no low readings. The hearing aids help most in conversation. He started the adult day program two days a week and likes the exercise group. The dilated eye examination booked after intake was missed: the clinic called the day before, but nobody at home remembered on the morning, and he no longer drives himself. He would like his Tdap today. **S**

| Element | Detail |
|---|---|
| Donepezil | 5 mg for five weeks; no side effects |
| Hemoglobin A1c | 6.9%, from 6.4% |
| Home glucose | 120 to 170 mg/dL; no lows |
| Hearing aids | Worn daily |
| Eye examination | Missed |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No nausea, diarrhea or weight loss |
| Cardiovascular | Negative | No dizziness or fainting |
| Neurological | Positive | Memory loss unchanged; no falls |
| Psychiatric | Negative | Mood good; enjoys the day program |

4 systems reviewed. **S**

## Current medications

- Metformin 1,000 mg oral tablet, one tablet twice daily with meals **S**
- Lisinopril 20 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Donepezil 10 mg oral tablet, one tablet at bedtime **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/76 mmHg; pulse 64 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 76.2 kg; BMI 23.5 kg/m². All vital signs are synthetic.

Hemoglobin A1c: 6.9% (high). All results are synthetic.

## Change since baseline

- Hemoglobin A1c: 6.4% (high) at baseline, 6.9% (high) at this visit **S**

## Immunizations given today

- Tdap vaccine, deferred from the preventive visit at his request **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 128/76; pulse 64 and regular; weight 76.2 kg |
| Mental status | Cheerful; follows conversation better with the hearing aids |
| Gait | Steady |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Alzheimer's disease with early onset** (G30.0). Donepezil 5 mg tolerated for five weeks; pulse 64. **S**
   - Donepezil 10 mg at bedtime.
   - Call for nausea, loose stools, dizziness or a pulse below 55.
2. **Type 2 diabetes** (E11.9). Hemoglobin A1c 6.9% off glipizide, within his goal of under 8.0%, with no low readings. **S**
   - Continue metformin.
   - Hemoglobin A1c in six months.
   - Eye examination re-booked with paratransit and a same-morning reminder call to his care partner.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA, MMSE) | At diagnosis, then yearly, or sooner with change | Up to date | Next in a year |
| Medication safety | Medicine review for anticholinergic and sedating drugs (Beers) | Every visit | Completed today | No anticholinergic or sedating drugs |
| Survey | Behavioral and psychological symptoms (NPI-Q items) | Every visit | Completed today | None |
| Medication safety | Cholinesterase inhibitor: benefit, nausea, diarrhea, dreams, pulse | Each follow-up and each dose change | Completed today | Five weeks on 5 mg without side effects; pulse 64; raised to 10 mg today |
| Self-management | Driving, firearm and home safety | At diagnosis and each follow-up | Completed today | Not driving; no firearm in the home; stove shut-off fitted |
| Self-management | Care partner support and burden (Zarit, narrative) | At diagnosis, then at least yearly | Completed today | Adult day program two days a week; caregiver class started |
| Self-management | Advance care planning | At diagnosis; revisit yearly and at changes | Up to date | Completed at the preventive visit two weeks ago |
| Laboratory | Hemoglobin A1c, goal under 8.0% for an older adult with cognitive impairment, and hypoglycemia review | Every three months after a therapy change; every six months when stable | Completed today | 6.9%, from 6.4%, off glipizide; no low readings |
| Examination | Blood pressure, goal under 130/80 mmHg | Every visit | Completed today | 128/76 mmHg |
| Laboratory | Potassium and creatinine on lisinopril and metformin | Yearly, and after acute illness or dehydration | Up to date | Normal at intake |
| Examination | Dilated diabetic eye examination | Every one to two years without retinopathy | Deferred | The dilated eye examination requested at intake was missed because he no longer drives and the appointment was forgotten on the morning. No harm is known: he has no visual symptoms and his diabetes is well controlled, but retinopathy cannot be excluded until he is examined. Corrective action: re-booked with paratransit, a same-morning reminder call to his care partner, and the appointment added to the day program's calendar |
| Self-management | Exercise and social activity | Every visit | Completed today | Day program exercise group and daily walks |

## Goal progress

- Find the cause of the memory loss and explain it to him in a way he can take in. Outcome by 2026-08-18: Alzheimer's disease confirmed by amyloid PET; disclosed with his care partner present, at his request, with written notes. **S**
- No hypoglycemia, with hemoglobin A1c under 8.0%. In progress; target 2026-10-27. **S**
- Stay safe: no driving and no firearm in the home. Outcome by 2026-08-18: He stopped driving and the handgun was removed from the home. **S**
- Keep his days full and give his care partner regular breaks. In progress; target 2026-10-27. **S**

## Medication changes

- Stopped: Donepezil 5 mg oral tablet, one tablet at bedtime **S**
- Started: Donepezil 10 mg oral tablet, one tablet at bedtime **S**

## Guideline basis

- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024), Alzheimer's Association (Alzheimers Dement 2025;21(1):e14337)
- CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026), Aether Forge
- 13. Older Adults: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1):S277-S296)
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society (Journal of the American Geriatrics Society)
- Practice Parameter update: Evaluation and management of driving risk in dementia (2010), American Academy of Neurology (Neurology 2010;74(16):1316-1324)
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Tdap given today. Eye examination as re-booked. Sixteen-week review in five weeks. Call for side effects of the higher donepezil dose. **S**
- Next scheduled visit 2026-10-27: sixteen-week review: medicines, kidneys, mood, caregiver strain and the plan. **S**
